TY - JOUR
T1 - Development of PARP inhibitors in oncology
AU - Rodon, Jordi
AU - Iniesta, Maria D.
AU - Papadopoulos, Kyriakos
N1 - Funding Information:
K Papadopoulos has received research funding from Pfizer and BiPar Sciences.
Funding Information:
M Iniesta is supported by a grant from Alfonso Martin Escudero Foundation, Madrid, Spain. We would like to thank Anthony Tolcher for the opportunity of conducting several trials with PARP inhibitors and for sharing his experience. We would also like to thank Judit Balmaña for critically reviewing this manuscript.
PY - 2009/1
Y1 - 2009/1
N2 - Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA repair mechanisms by detecting and initiating repair after DNA strand breaks. Inhibition of PARP in DNA repair-defective tumors (like those with BRCA1 or BRCA2 mutations) can lead to gross genomic instability and cell death. Likewise, combining PARP inhibition with cytotoxic agents such as chemotherapy or radiation therapy is synergistic in many preclinical models. Several drugs designed to inhibit PARP are currently in clinical development, many following a development path different from that of typical anticancer agents. In this review we will focus on the early clinical data from PARP inhibitors that are entering clinical trials, the potential tumors they might target, their combination with other drugs and the different biomarkers that are being explored. Concepts such as 'BRCAness', synthetic lethality, Phase 0 trials and pharmacodynamic markers will be discussed in the context of the development of PARP inhibitors.
AB - Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA repair mechanisms by detecting and initiating repair after DNA strand breaks. Inhibition of PARP in DNA repair-defective tumors (like those with BRCA1 or BRCA2 mutations) can lead to gross genomic instability and cell death. Likewise, combining PARP inhibition with cytotoxic agents such as chemotherapy or radiation therapy is synergistic in many preclinical models. Several drugs designed to inhibit PARP are currently in clinical development, many following a development path different from that of typical anticancer agents. In this review we will focus on the early clinical data from PARP inhibitors that are entering clinical trials, the potential tumors they might target, their combination with other drugs and the different biomarkers that are being explored. Concepts such as 'BRCAness', synthetic lethality, Phase 0 trials and pharmacodynamic markers will be discussed in the context of the development of PARP inhibitors.
KW - BRCA1
KW - BRCA2
KW - BRCAness
KW - PARP inhibitor
KW - Pharmacodynamics
KW - Poly (ADP-ribose) polymerase
UR - http://www.scopus.com/inward/record.url?scp=67649379011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649379011&partnerID=8YFLogxK
U2 - 10.1517/13543780802525324
DO - 10.1517/13543780802525324
M3 - Review article
C2 - 19053880
AN - SCOPUS:67649379011
SN - 1354-3784
VL - 18
SP - 31
EP - 43
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 1
ER -